Merck's Bridion Wins FDA Approval, Finally
This article was originally published in Scrip
Executive Summary
After previously being rejected three times by the FDA, Merck & Co.'s Bridion (sugammadex), an injectable drug intended to reverse neuromuscular blockade induced by rocuronium or vecuronium – agents used during certain types of surgical procedures – finally made it across the US regulatory agency's finish line on Dec. 15.